ADA Scientific Sessions 2026 Abstract

Efficacy and Safety of the GlP-1/GIP Dual Agonist HRS9531 in Overweight/Obese Chinese Patients with Polycystic Ovary Syndrome

By Jingjing Li, Hongwei Jiang

Trial in peopleInterventions

The paper

Jingjing Li, Hongwei Jiang

Luoyang

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1815-P

doi.org/10.2337/db26-1815-p

Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine4 Oct 2026
Retatrutide reduces weight and pain in adults with obesity
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes